 Home > Encyclopedia > Beraprost sodium

Beraprost sodium

Beraprost sodium structure

CAS No:
88475-69-8
Formula:
C24H30O5.Na
Chemical Name:
Beraprost sodium
Synonyms:
1H-Cyclopenta[b]benzofuran-5-butanoic acid,2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-yn-1-yl)-,sodium salt (1:1);1H-Cyclopenta[b]benzofuran-5-butanoic acid,2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-,monosodium salt;TRK 100;Beraprost sodium;Beraprost sodium salt;ML 1129;Procylin;MDL 201129;Dorner;Careload;Berasus
Categories:
Active Pharmaceutical Ingredients > Hormones and the Endocrine System

Description

White Solid

Beraprost sodium is the organic sodium salt of beraprost. It is used in the treatment of chronic arterial occlusive disease and primary pulmonary hypertension in Japan. It has a role as an antihypertensive agent, a platelet aggregation inhibitor, a prostaglandin receptor agonist, a vasodilator agent and an anti-inflammatory agent. It contains a beraprost(1-).|Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.

Beraprost sodium Basic Attributes

Molecular Weight：

420.47

Exact Mass：

420.19100

UNII：

15K99VDU5F

DSSTox ID：

DTXSID2048585

Characteristics

PSA：

89.82000

XLogP3：

1.95120

Appearance：

white solid

Melting Point：

204-206°C

Boiling Point：

572.1ºC at 760 mmHg

Flash Point：

193.1ºC

Storage Conditions：

Amber Vial, -20°C Freezer, Under Inert Atmosphere

Safety Information

GHS Classification：

|Danger|H300 (100%): Fatal if swallowed [Danger Acute toxicity, oral]|P264, P270, P301+P310, P321, P330, P405, and P501|Aggregated GHS information provided by 3 companies from 1 notifications to the ECHA C&L Inventory.

Drug Information

Drug Indication：

For the treatment of pulmonary hypertension.

Pharmacology：

Beraprost is a stable, orally active prostacyclin analogue with vasodilatory, antiplatelet and cytoprotective effects. Beraprost is generally well tolerated and appears to be an effective agent in the treatment of patients with Buerger's disease and arteriosclerosis obliterans. Comparative data from a large randomised trial indicated that the drug appears as effective as ticlopidine in patients with these conditions. In patients with intermittent claudication, significant benefits of beraprost compared with placebo were reported in a randomised clinical trial; however, the use of beraprost in these patients is not supported by recent preliminary unpublished data from a large, phase III, placebo-controlled study. Limited data suggest some efficacy with long-term beraprost treatment of patients with PAH, where options are few and where oral administration of the drug could be a considerable advantage over intravenous prostacyclin (PGI2) therapy.

MeSH：

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)|Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)

Absorption：

Oral bioavailability is 50–70%.

Biological Half-Life：

35–40 minutes

Mechanism of Action：

Beraprost acts by binding to prostacyclin membrane receptors ultimately inhibiting the release of Ca²⁺ from intracellular storage sites. This reduction in the influx of Ca²⁺ has been postulated to cause relaxation of the smooth muscle cells and vasodilation.

MeSH Entry Terms：

4-(1,2,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyloct-6-yne-1-enyl)-5-cyclopenta(b)benzofuranyl)butyrate

Beraprost sodium Use and Manufacturing

Uses

Platelet aggregation inhibitor; stable analog of Prostacyclin. Antithrombotic; vasodilator (peripheral).

Use Classification：

Human drugs -> Rare disease (orphan)

Computed Properties

Molecular Weight:420.5
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:5
Rotatable Bond Count:8
Exact Mass:420.19126830
Monoisotopic Mass:420.19126830
Topological Polar Surface Area:89.8
Heavy Atom Count:30
Complexity:665
Defined Atom Stereocenter Count:5
Undefined Atom Stereocenter Count:1
Defined Bond Stereocenter Count:1
Covalently-Bonded Unit Count:2
Compound Is Canonicalized:Yes

Drug Function and Efficacy

Extract from the above information

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Beraprost Sodium Tablets
Indication	It has synergistic effects with the following drugs: anticoagulants, warfarin, etc., antiplatelet drugs, aspirin, ticlopidine, etc., thrombolytic agents, urokinase, etc. There is a possibility of increased bleeding tendency, so it should be closely observed. If abnormalities are found, appropriate measures such as reducing the dose or stopping the combined medication should be given. It may have a synergistic effect with prostaglandin I2 preparations, and combined use may cause a decrease in blood pressure, so blood pressure needs to be closely monitored.

Beraprost Sodium Tablets

Indication

It has synergistic effects with the following drugs: anticoagulants, warfarin, etc., antiplatelet drugs, aspirin, ticlopidine, etc., thrombolytic agents, urokinase, etc. There is a possibility of increased bleeding tendency, so it should be closely observed. If abnormalities are found, appropriate measures such as reducing the dose or stopping the combined medication should be given. It may have a synergistic effect with prostaglandin I2 preparations, and combined use may cause a decrease in blood pressure, so blood pressure needs to be closely monitored.

Beraprost Sodium
Indication	It has synergistic effects with the following drugs: anticoagulants, warfarin, etc., antiplatelet drugs, aspirin, ticlopidine, etc., thrombolytic agents, urokinase, etc. There is a possibility of increased bleeding tendency, so it should be closely observed. If abnormalities are found, appropriate measures such as reducing the dose or stopping the combined medication should be given. It may have a synergistic effect with prostaglandin I2 preparations. When used together, it may cause a decrease in blood pressure, so blood pressure needs to be closely monitored.
Specifications	API

Beraprost Sodium

Indication

It has synergistic effects with the following drugs: anticoagulants, warfarin, etc., antiplatelet drugs, aspirin, ticlopidine, etc., thrombolytic agents, urokinase, etc. There is a possibility of increased bleeding tendency, so it should be closely observed. If abnormalities are found, appropriate measures such as reducing the dose or stopping the combined medication should be given. It may have a synergistic effect with prostaglandin I2 preparations. When used together, it may cause a decrease in blood pressure, so blood pressure needs to be closely monitored.

Specifications

API

Beraprost Sodium Tablets
Specifications	20 micrograms

See More Related Drugs

Registered Holders

EUROAPI Hungary Ltd.

Japan
Active
NEWCHEM S.P.A.

Italy
Active
TORAY INDUSTRIES, INC.

Japan
Active

See More Registered Holders

Recommended Suppliers of Beraprost sodium

HANGZHOU LEAP CHEM CO., LTD. Contact Supplier

CN
5 YRS

Business licensed

Trader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives

Beraprost sodium

CAS No.: 88475-69-8

Content: 99.00%

Inquiry
Shaanxi Cuikang Pharmaceutical Technolog Contact Supplier

CN
4 YRS

Business licensed Certified factory

Manufactory Supplier of Cosmetics raw materials,Pesticide intermediate,Photoelectric material,pharmaceutical intermediates,Raw materials for food and health products,Polymer materials,Fine Chemicals,Synthetic customization

PROCYLIN

CAS No.: 88475-69-8

Grade: Industrial Grade

Content: 98%

Inquiry
Henan Lihao Chem Plant Limited Contact Supplier

CN
5 YRS

Business licensed

Trader Supplier of PVC resin,pvc paste resin,melamine

Beraprost sodium 99% see COA kanbei

CAS No.: 88475-69-8

Grade: Industrial Grade

Content: 99%

Inquiry
Shandong Airuike Chemical Co., Ltd. Contact Supplier

CN
3 YRS

Business licensed

Trader Supplier of api,Intermediates,Organic Chemistry,Inorganic Chemistry,Daily Chemicals,Cosmetic Raw Materals,CATALYST AND AUXILIARY,FLAVORS AND FRAGRANCES,Chemical Pesticides,ADDITIVE

Beraprost Sodium CAS 88475-69-8

CAS No.: 88475-69-8

Grade: Pharmaceutical Grade

Content: 99%

Inquiry